Sparks commentary

Healthcare

Sparks

FDA approves Vertex’s (NASDAQ: VRTX) pain drug
Published by Arron Aatkar, PhD

The US FDA has approved Vertex’s suzetrigine, now called Journavx, for the treatment of adults with moderate-to-severe acute pain. Vertex has spent many decades in the challenging field of pain management and the approval of  Journavx represents a significant milestone in public health, especially following the opioid epidemic in the US.

 

Latest

Industrials | Comment

Earnz (AIM: EARN) – Proposed acquisition of Zero Carbon Group

Industrials | Comment

Electro Optic Systems (ASX: EOS) announces US$45m order win

Financials | Comment

Revolut secures full UK banking licence

Healthcare | Comment

OSE Immunotherapeutics (PAR: OSE) confirms new CEO